Tech IPOs, public-market debuts, and what each one means for the exit environment.
Sam Altman told reporters at DevDay that OpenAI won't go public until it can make "confident safety claims" about its models, pushing the listing past his own earlier 2027 target with no new date attached.
Oura's shelved IPO doesn't mean the 2026 exit window is shut -- SpaceX, Nscale, Fidelis Partnership and Switch are all still lined up behind it.
Anthropic's public S-1 shows compute agreements with SpaceX.AI worth up to $120.5 billion through 2029, above the $84.5 billion reported from its confidential draft.
Oura postponed its IPO hours before pricing despite the offering being roughly 4x oversubscribed, citing market uncertainty rather than weak demand.
Five blank-check acquisition companies filed or amended S-1 registrations with the SEC in a single 48-hour window, the largest cluster of new SPAC paper this year.
Anthropic's confidential IPO filing targets a $2 trillion valuation and reportedly discloses $518 billion in infrastructure commitments, while devoting a third of the document to warning its own models could pose existential risk.
Rent the Runway filed an amended S-1 registration statement on September 28, the first amendment to the registration for the $15 million rights offering to existing shareholders it filed on September 11.
Rent the Runway's largest shareholders agreed to fully backstop a $15 million rights offering at a $3.55 minimum price, guaranteeing the raise closes regardless of shareholder uptake.
This fall's IPO pipeline is barbell-shaped -- trillion-dollar AI labs at one end, a wave of sub-$50M SPAC and shell filings at the other -- with almost nothing filling the middle where most VC-backed startups actually sit.
The SEC logged 12 new S-1 filings and 11 S-1/A or 424B4 amendments in a single late-September window, while only one name -- ADARx -- actually priced (Oura has set a $40-$44 range and is expected to price this week), a widening gap between filing volume and real liquidity.
AbbVie's concurrent $89 million private placement pushed ADARx's total fresh capital from its $446M priced IPO to $535.3 million, with the pharma giant taking a stake alongside the public listing.
This week's SEC filing queue was dominated by blank-check SPACs, a REIT and micro-cap biotechs, not venture-backed growth companies, a reminder that genuine venture-scale IPO supply stays thin even as 2026's dollar totals near multi-year highs.
Oura prices its Nasdaq debut this week at a targeted $15.6B valuation on real GAAP profit and 74% revenue growth -- unusually strong for hardware -- but a $924M reported net loss from a stock buyback accounting quirk complicates the pitch.
Nscale disclosed a $3.36 billion pre-IPO convertible round led by Third Point, its second big financing in ten days as it pushes toward a US listing targeting a $25 billion valuation.
ADARx Pharmaceuticals priced an upsized $446 million IPO at $17 a share and began trading on the Nasdaq as ADRX, joining the fall biotech IPO window alongside its existing AbbVie drug partnership.
2026's IPO market has priced 109 offerings raising $146.5 billion through mid-September, and this week's cohort -- a mix of pops, declines and a pulled listing -- shows the window staying open but increasingly selective.
The same week produced a 19% pop for Ligent, a 12% decline for Electra Therapeutics, and a pulled listing for Bamboo Insurance -- evidence the 2026 IPO window is open but pricing power now depends entirely on the individual deal.
Six live IPO storylines this week produced wildly different outcomes -- from a 19% Hong Kong pop to a pulled US deal -- and the spread says this fall's IPO window rewards individual fundamentals, not just good timing.
Firmus Grid's draft prospectus forecasts a $77 million first-half loss even as the Nvidia-backed data center operator priced its Australian IPO at A$11.00 a share to raise A$7.1 billion ($4.94 billion), a $30.6 billion equity valuation (about $60 billion including debt), according to a term sheet reviewed by Reuters.
ADARx Pharmaceuticals priced an upsized IPO at $17 per share, raising $446.3 million, with AbbVie separately buying up to 4.9% of the company in a concurrent private placement ahead of Thursday's Nasdaq debut.
Anthropic is seeking Palantir-style voting control for its seven co-founders ahead of a planned IPO, a structure that would let founders keep outsized control even as public shareholders buy in.
Eli Lilly indicated interest in buying up to $100 million of Oura's IPO shares, and updated filings show the smart-ring maker is actually profitable, with $60.8 million in net income over nine months.
Six companies are mid-IPO-process on US and Indian exchanges this week, from Oura's $15.6B roadshow to Bamboo Insurance's all-secondary listing, and the spread across sectors says the fall IPO window is genuinely open.
Shares of India's National Stock Exchange rose only about 1.8% on their debut day despite the IPO being 5.7 times oversubscribed, a muted pop that confirms the gap between pre-listing demand and the price public markets actually paid.
Bamboo Insurance Services postponed its planned NYSE listing on the day it was set to price, citing financial-market volatility, after marketing an all-secondary offering targeting a roughly $3.24 billion valuation.
India's National Stock Exchange priced its IPO at the top of its range, valuing the exchange at $46 billion -- below the roughly $55 billion some earlier estimates floated -- after the $2.3 billion offering drew more than $10 billion in bids.
Live Oak Acquisition Corp VI priced its $200 million SPAC IPO on Nasdaq, with units beginning to trade under ticker LOVIU a month after its S-1 filing, adding another blank-check vehicle to 2026's active new-issue market.
SeeQC filed an amended S-1/A on September 22, nearly three months after its original IPO filing, as the company works in parallel toward a proposed merger with Allegro and prepares to list on Nasdaq under ticker SEQC.
Oura launched its IPO roadshow with a $40-$44 price range targeting a $15.62 billion valuation, with Nasdaq trading expected the week of September 28, and disclosed revenue of $1.21 billion over nine months, up 74% year over year.
SoftBank-owned SB Energy has finished SEC review of its IPO registration and plans to begin roadshow marketing next, moving its Nasdaq listing under ticker SBE closer to pricing at a targeted valuation of $50 billion or more.
Accelevation Holdings, which makes power distribution equipment for hyperscale and AI data centers, filed for a Nasdaq IPO seeking up to $660 million after posting $727 million in revenue and 147% growth, backed by Olympus Partners.
Ligent Technologies, a Qingdao-based maker of the optical transceivers that link servers inside AI data centers, raised $727 million in a Hong Kong IPO and saw its shares jump as much as 19% on debut.
This fall's IPO pipeline is splitting between companies actually pricing and trading -- newcleo, Electra Therapeutics -- and a growing backlog of filed-but-not-priced names including Nscale and Wella, some sitting for weeks without terms.
Recent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.
Newcleo, a French-Italian startup building lead-cooled small modular reactors fueled by recycled nuclear waste, began trading on Nasdaq under ticker NWCL after closing a $2.4 billion SPAC merger with NewHold Investment Corp III.
ADARx Pharmaceuticals set terms for a $350 million IPO at $15 to $17 a share, seeking to fund Phase 2 trials of its lead siRNA therapy for rare renal disease, after posting an $87.7 million net loss on $6.1 million of collaboration revenue.
Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.
Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia and Qatar's sovereign wealth fund, filed for a US IPO at a roughly $5.49 billion market cap amid a busy fall pipeline of AI-adjacent biotechs.
Silicon Valley Acquisition Corp. II filed an S-1 for a $220 million SPAC IPO targeting fintech, crypto, AI infrastructure and energy-transition businesses, led by former Cohen & Company investment banking head Dan Nash.
Nvidia is buying an additional $1.5 billion in SB Energy shares ahead of the SoftBank-backed data center developer's US IPO, bringing its total commitment to $3 billion at a price equal to 90% of the offering price.
Anthropic's IPO slid a second time to November as ADARx priced at a $1.74 billion target and two more biotechs filed to go public, showing this fall's IPO pipeline growing in volume even as its biggest name keeps slipping.
Oura set terms to raise up to $2.2 billion at a $15.62 billion valuation, but 36.5 million of the 50 million shares on offer are being sold by existing investors and employees, not the company.
Retail investors are spreading money across multiple brokerages hoping for pre-IPO exposure to Anthropic and OpenAI, a strategy that left one investor with a fraction of his expected SpaceX gains after lockups and technical problems.
Bamboo Insurance is marketing 35 million shares at $18-$20 for its NYSE debut under ticker BMB, but every share is being sold by backers CVC Capital Partners and White Mountains -- the company gets no proceeds.
TRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.
ADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.
Anthropic is sliding its IPO timeline a second time, from mid-October to November, as it waits to show investors a full quarter of results before pricing a listing still targeted at roughly a $2 trillion valuation.
Orion180 priced its IPO at $12 a share -- below its $15-$17 target -- raising $240 million, then opened at $11.50 for a $1.14 billion valuation on its first day of Nasdaq trading.
Nscale filed its S-1 for a New York Stock Exchange listing under ticker NSCL, disclosing $103.4 billion in contracted AI-compute revenue after Anthropic signed a $45 billion capacity deal in August.
The week of September 14-18 logged 35 US IPO pricings, part of a 2026 pace -- 239 IPOs, 331 filings -- tracking toward the strongest year for new listings since the 2021 boom.
Oura's roadshow is still waiting on a price range and Anthropic has pushed to mid-October, leaving the two most-watched listings of the year both sitting past their original fall targets at the same time.
The Dow rose 316 points and the Nasdaq jumped 1.7% Thursday as markets rebounded from the Fed's first rate hike in three years, with falling oil prices and bond yields lifting tech shares into Friday.
The Dow fell more than 630 points and the S&P 500 slipped 0.5% the day the Fed hiked rates, before futures pointed to a rebound the following morning -- a whipsaw that left AI and chip stocks especially exposed.
Anthropic is finalizing an expanded $15 billion revolving credit facility as it prepares an IPO prospectus that could target a valuation north of $2 trillion this fall.
Nvidia's Q2 revenue jumped 106% and Oracle's cloud infrastructure revenue grew 121% with GPU utilization near 98% -- the clearest evidence yet that AI infrastructure spending hasn't slowed despite a volatile week for the stocks.
Chip and data-center stocks fell after Amodei's AI-slowdown essay Monday, then again after Wednesday's Fed hike, even as individual names like Semtech and AMD posted double-digit gains on company-specific earnings news.
The 10-year Treasury yield climbed above 5% ahead of the Fed's rate decision, its highest level since July 2007, as a global bond selloff intensified on energy prices, inflation risk and fiscal concerns.
SpaceX has set September 22 for Starship's first full orbital flight attempt, the newly public company's highest-stakes technical milestone since its record-breaking June IPO.
238 IPOs have priced on U.S. markets in 2026 through mid-September, down about 4% from the same point in 2025 -- even as SpaceX's $2.1 trillion listing alone outraised the last two years of U.S. IPOs combined.
The 10-year Treasury yield climbed to 5.041% and oil held near $107.55 as traders priced a 92% chance of a Fed rate hike Wednesday, up from 88% odds a day earlier, with futures pointing to a lower open.
